In this week's episode we’ll learn more about the use of ruxolitinib plus dexamethasone to treat newly diagnosed patients with adult hemophagocytic lymphohistiocytosis; lysine-specific demethylase-1 inhibitors as a potential new class of therapies for sickle cell disease and other beta-globinopathies; and insights into clinical characteristics of patients with von Willebrand factor levels that are lower than normal but higher than those typically used to diagnose von Willebrand disease.
Featured Articles:
View all episodes
By American Society of Hematology
4.1
4949 ratings
In this week's episode we’ll learn more about the use of ruxolitinib plus dexamethasone to treat newly diagnosed patients with adult hemophagocytic lymphohistiocytosis; lysine-specific demethylase-1 inhibitors as a potential new class of therapies for sickle cell disease and other beta-globinopathies; and insights into clinical characteristics of patients with von Willebrand factor levels that are lower than normal but higher than those typically used to diagnose von Willebrand disease.
Featured Articles:
11,147 Listeners
140 Listeners
318 Listeners
499 Listeners
75 Listeners
26 Listeners
1,157 Listeners
2 Listeners
363 Listeners
373 Listeners
1 Listeners
48 Listeners
190 Listeners
30 Listeners
4 Listeners